RESEARCH NEWS UPDATE Encouraging Trial Results for Potential Lupus Drug Iberdomide In a Phase 2a clinical trial, the drug iberdomide was found to be safe and effective for the treatment of lupus. With increasing doses, participants’ lupus disease activity improved while negative reactions were uncommon and mostly mild. The study included 17 people with lupus, and researchers assessed their symptoms and tolerance of the treatment. Some people received a placebo (an inactive treatment) while others received differ-
ent doses of iberdomide. At all dose levels, participants benefitted from improved disease activity compared to the placebo group and their baseline disease measures. Blood levels of B cells (white blood cells that attack invading viruses, bacteria and toxins) and markers of inflammation decreased as treatment dosage increased – good signs that the treatment is working.
included nausea, diarrhea and upper respiratory tract infections. More moderate to severe reactions occurred in the highest dose groups. Iberdomide shows early promise as a potential therapy for lupus, and the latest trial results indicate its worth continued investigation.
The most common negative reactions to the treatment LIVING WITH LUPUS MAGAZINE
21
